Similarly, the NEWBEAT study, which evaluated nivolumab plus bevacizumab and paclitaxel in HER2-negative breast cancer patients, found that the incidence of any-grade hypertension was as high as 30%, with 14% being grade 3/4.17 This evidence concerns the gene ERBB2 and hypertensive disorder.